University of Michigan

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Michigan sits in the top decile of US sponsors by registered trial count (#19 of 15,742 sponsors by registered trial count).

1,327 total trials 179 currently recruiting 971 completed early-phase tilt top decile by trial count

University of Michigan: 1,327 sponsored US clinical trials, 179 recruiting.

University of Michigan sponsors 1,327 registered US clinical trials on ClinicalTrials.gov, 179 of them currently recruiting, and 971 completed. 94 of these trials are in Phase 3-4 (later-stage) and 159 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 15 trials.

Top-decile sponsor footprint

University of Michigan ranks in the top decile of sponsors by registered trial count (#19 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 64/100

971 of 1,083 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,327 total, page 24 of 27

COMPLETED Phase 2

Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma

NCT00794950

TERMINATED Phase 4

Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients

NCT00820612

TERMINATED

Evaluation of Radiology Resident Anxiety When Beginning Emergency Room (ER) Call

NCT00859066

COMPLETED Phase 2

Positional Therapy After Stroke

NCT01047709

COMPLETED NA

Role of Exercise in Diastolic Heart Failure

NCT01047631

COMPLETED

Imaging of Soft Tissues

NCT00796094

COMPLETED

Risk Factors for Implant Bone Loss in Patients With Diabetes Mellitus

NCT00933491

COMPLETED NA

Effects of Earplugs on Sleep and Sleep Apnea

NCT01062854

COMPLETED Phase 2

Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality

NCT00782795

TERMINATED Phase 4

Effects of Fish Oil on Post Ablation Arrhythmias

NCT00791089

COMPLETED NA

Seasonal Influenza Vaccination Reminders for Children With High-risk Conditions

NCT01431183

COMPLETED NA

Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects

NCT00815854

COMPLETED Phase 2

Micronutrients to Prevent Noise-induced Hearing Loss

NCT00808470

COMPLETED

Diffusion Tensor Imaging of Sural Nerves in Diabetic Peripheral Neuropathy

NCT00835757

COMPLETED

PET Study of Non-Motor Symptoms of Parkinson Disease

NCT01565473

COMPLETED

Differentiating Recurrent Brain Tumor Versus Radiation Injury Using MRI

NCT00760409

COMPLETED Phase 1

P300 Brain Computer Interface Keyboard to Operate Assistive Technology

NCT00860951

COMPLETED Phase 2

Does Fish Oil Prevent Depression in Pregnancy and Postpartum?

NCT00711971

COMPLETED NA

Community Approaches to Cardiovascular Health: Pathways to Heart Health

NCT02036593

COMPLETED Phase 4

Intraoperative Glucose Control in Liver Transplant

NCT00780026

COMPLETED Phase 2

Chamomile for Chronic Primary Insomnia

NCT01286324

COMPLETED NA

Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury

NCT00735670

COMPLETED NA

Developing Biomarkers for Fibromyalgia

NCT00932061

COMPLETED NA

Evaluation of Exenatide in Patients With Diabetic Neuropathy

NCT00855439

COMPLETED Phase 1

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

NCT00755911

COMPLETED

The Pathogenesis of Idiopathic Dry Eyes

NCT01254201

COMPLETED Phase 1

The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy

NCT00696410

COMPLETED NA

Bispectral Index (BIS) Versus Electronic Alerts in the Prevention of Anesthesia Awareness: the Michigan Awareness Control Study

NCT00689091

COMPLETED

Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS)

NCT00809224

COMPLETED Phase 2

Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria

NCT00625820

TERMINATED NA

Initial Versus Delayed Operation for Treatment of Complicated Appendicitis In Children

NCT00540189

COMPLETED NA

Magnetic Resonance Spectroscopy, Perfusion, and Diffusion Tensor Imaging in Neuropsychiatric Lupus

NCT00730002

COMPLETED

Identifying Brain and Genetic Markers of Sertraline Treatment Response in People With Social Anxiety Disorder

NCT00872131

COMPLETED

Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis

NCT00667134

COMPLETED NA

Sonographic Features of Normal Soft Tissues of the Feet

NCT00719004

TERMINATED NA

Anesthesia and Functional Connectivity: An Analysis of fMRI Changes

NCT02196259

COMPLETED

Upright Versus Supine Exercise Testing in Fontan-palliated Patients

NCT00633815

COMPLETED NA

Expression of Angiogenic Biomarkers During Healing of Intra-Oral Soft Tissue Engineered Grafts

NCT01134081

COMPLETED NA

Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome

NCT00670800

COMPLETED Phase 4

The Influence of Dimensional Anatomic Variables on the Outcomes of Maxillary Sinus Grafting Procedures

NCT00868777

COMPLETED NA

Breast Lesion Analysis for Tomosynthesis Mammography

NCT00723541

TERMINATED

Evaluating Outcomes in the Placement of Boomerang Percutaneous Device

NCT00732628

COMPLETED NA

The Women's Healthy Lifestyle Study

NCT00583726

COMPLETED

Neovascularization Patterns in Corneal Graft Rejection

NCT01695655

COMPLETED Phase 3

PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease

NCT00554853

COMPLETED Phase 3

Self-Care to Prevent Birth-Related Urinary Incontinence in Diverse Women

NCT00763984

COMPLETED

Preliminary Longitudinal Validation of Biomarkers Predictive of Barrett's Esophagus

NCT00844077

COMPLETED NA

Age-Specific Strategies for Immunization Reminders and Recalls

NCT01770496

COMPLETED NA

Femtosecond Laser Assisted Keratoplasty

NCT00802776

COMPLETED NA

A System for Lengthening Contraction Training of Muscle

NCT00575107

← Previous Page 24 of 27 Next →

Phase Distribution

PhaseTrial count
Phase 1 79
Phase 2 80
Phase 3 25
Phase 4 69

What is open in the University of Michigan pipeline

179 recruiting of 1,327 indexed (13% open); 971 completed (73%).

Phase mix: 94 late (III/IV) vs 159 early (I/II) (early-phase heavy).

Top condition: Depression (15 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Michigan: open-pipeline peers nationwide

Peers matched on 1,327 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

University of Michigan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 0%5%10%15%20%25% Total trials Recruiting share University of MichiganEli Lilly and CompanyGlaxoSmithKlineAstraZenecaUniversity of Colorado, DenverWayne State UniversityCase Comprehensive Cancer CenterAlbany Medical CollegeTaiho Oncology
University of Michigan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Michigan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,327 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

What to do with this University of Michigan page

1,327 registered trials is a research-attention snapshot, not an endorsement of University of Michigan or any single study.

  • 179 of University of Michigan's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition University of Michigan studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Michigan pipeline card: 1,327 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.